Baker Bros. Advisors LP Centessa Pharmaceuticals PLC Transaction History
Baker Bros. Advisors LP
- $9.02 Billion
- Q4 2024
A detailed history of Baker Bros. Advisors LP transactions in Centessa Pharmaceuticals PLC stock. As of the latest transaction made, Baker Bros. Advisors LP holds 1,227,178 shares of CNTA stock, worth $20 Million. This represents 0.23% of its overall portfolio holdings.
Number of Shares
1,227,178
Previous 1,227,178
-0.0%
Holding current value
$20 Million
Previous $19.6 Million
4.75%
% of portfolio
0.23%
Previous 0.21%
Shares
4 transactions
Others Institutions Holding CNTA
# of Institutions
118Shares Held
124MCall Options Held
7KPut Options Held
220K-
Medicxi Ventures Management (Jersey) LTD20MShares$325 Million73.44% of portfolio
-
Index Venture Life Associates Vi LTD St. Helier, Y99.96MShares$162 Million99.89% of portfolio
-
General Atlantic LLC New York, NY9.68MShares$158 Million5.81% of portfolio
-
Perceptive Advisors LLC New York, NY6.35MShares$103 Million3.55% of portfolio
-
First Light Asset Management, LLC Edina, MN5.81MShares$94.6 Million9.51% of portfolio
About Centessa Pharmaceuticals plc
- Ticker CNTA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 94,339,296
- Market Cap $1.54B
- Description
- Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines to patients. Its registrational pipeline products include Lixivaptan, a vasopressin V2 receptor small molecule inhibitor that is in Phase III clinical development for the treatment of autosomal dominant polycystic kidney disease; an...